Key result
Evinacumab cuts LDL-C by ~50% at 104 weeks in homozygous familial hypercholesterolemia.
Why the study?
The efficacy of evinacumab by genotype and LDLR function in patients with homozygous familial hypercholesterolaemia was assessed in this subanalysis of the ELIPSE open-label extension study.
Does evinacumab reduce LDL-C levels in patients with homozygous familial hypercholesterolaemia irrespective of genotype or LDLR function?
Cohort (n=116)
Open-label
Does evinacumab reduce LDL-C levels in patients with homozygous familial hypercholesterolaemia irrespective of genotype or LDLR function?
Answers are grounded in this paper and cite their sources.
Evinacumab provides rapid and sustained LDL-C reduction in patients with homozygous familial hypercholesterolemia, regardless of underlying genotype or LDLR function.
BACKGROUND AND AIMS: Homozygous familial hypercholesterolaemia (HoFH) is a rare genetic disorder caused primarily by variants in both alleles of the gene encoding the low-density lipoprotein receptor (LDLR). This subanalysis of the ELIPSE open-label extension (OLE) study assessed the efficacy of evinacumab, an angiopoietin-like 3 inhibitor, by genotype and LDLR function in patients with HoFH. METHODS: Patients aged ≥12 years with HoFH on stable lipid-lowering therapies received evinacumab 15 mg/kg intravenously every 4 weeks. Patients were grouped according to genotype: bi-allelic monogenic identical variants (true homozygous) or bi-allelic monogenic different LDLR variants (compound heterozygous); and by LDLR function: null/null variants resulting in <15% LDLR activity or negative/negative variants predicted to result in <2% LDLR activity. RESULTS: One hundred and sixteen patients enrolled in the OLE. At baseline, 55 (47.4%) had either identical bi-allelic variants in LDLR (n = 53) or LDLRAP1 (n = 2), and 41 (35.3%) had different bi-allelic LDLR variants. Median (Q1, Q3) LDL-C levels were reduced by -53.8% (-42.6%, -67.0%) and -58.1% (-41.5%, -65.9%) by Week 8 of evinacumab treatment in the identical (LDLR or LDLRAP1) and different (LDLR) bi-allelic variant groups, respectively, and remained low at Week 104 (-50.9% [-34.9%, -60.3%] and -47.3% [-34.8%, -67.5%], respectively). At baseline, 36 (31.0%) patients had null/null LDLR variants, and 19 (16.4%) patients had negative/negative LDLR variants. Evinacumab treatment also resulted in rapid and sustained decreases in median LDL-C levels to Week 104 in these subgroups. CONCLUSIONS: Evinacumab treatment resulted in sustained LDL-C reduction in patients with HoFH irrespective of genotype or LDLR function.
No takes yet. Share an insight, caveat, or question.
Kallend et al. (2026) conducted a cohort in Homozygous familial hypercholesterolaemia (HoFH) (n=116). Evinacumab was evaluated on Median LDL-C level reduction. Evinacumab /kg intravenously every 4 weeks reduced median LDL-C levels by 47.3% to 50.9% at 104 weeks in patients with homozygous familial hypercholesterolaemia, irrespective of genotype.
Synapse has enriched 10 related papers. Consider them for comparative context: